Treatment history
| TM | AFM | AFM subtypes | ||
| Grey matter | Mixed matter | |||
| N | 39 | 51 | 23 | 21 |
| First treatment | ||||
| Corticosteroids | 35 (90%) | 35 (69%) | 13 (57%) | 19 (90%) |
| Median months from onset (P25, P75) | 0 (0, 0), n=31 | 0 (0, 0), n=31 | 0 (0, 0), n=12 | 0 (0, 0), n=16 |
| Received one additional treatment | 19 (54%) | 15 (43%) | 6 (46%) | 6 (32%) |
| IVIG | 6 (32%) | 11 (73%) | 4 (67%) | 4 (67%) |
| PLEX | 13 (68%) | 4 (27%) | 2 (33%) | 2 (33%) |
| Received two additional treatments | 8 (23%) | 12 (34%) | 3 (23 %) | 9 (47%) |
| Corticosteroids → PLEX | 2 (25%) | 0 | 0 | 0 |
| PLEX →PLEX | 1 (12%) | 0 | 0 | 0 |
| IVIG →PLEX | 1 (12%) | 5 (42%) | 2 (67%) | 3 (33%) |
| PLEX →IVIG | 4 (50%) | 7 (58%) | 1 (33 %) | 6 (67%) |
| IVIG | 3 (8%) | 15 (29%) | 10 (43%) | 2 (10%) |
| Received one additional treatment | 0 | 5 (33%) | 3 (30%) | 1 (50%) |
| IVIG | 0 | 1 (20%) | 1 (33%) | 0 |
| PLEX | 0 | 1 (20%) | 1 (33%) | 0 |
| Corticosteroids | 0 | 3 (60%) | 1 (33%) | 1 (100%) |
| Received two additional treatments | 3 (100%) | 3 (20%) | 1 (10%) | 1 (50%) |
| Unknown → corticosteroids | 1 (33%) | 0 | 0 | 0 |
| Corticosteroids →PLEX | 2 (67%) | 1 (33%) | 0 | 1 (100%) |
| PLEX →IVIG | 0 | 1 (33%) | 1 (100%) | 0 |
| PLEX →corticosteroids | 0 | 1 (33%) | 0 | 0 |
AFM, acute flaccid myelitis; IVIG, intravenous immunoglobulin; PLEX, plasma exchange; TM, transverse myelitis.